PRIMARA: A Prospective Descriptive Observational Study to Review Mimpara (Cinacalcet) Use in Patients With Primary Hyperparathyroidism in Clinical Practice

• Status: Completed
• Trial end date: 2012-02-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a multicentre, descriptive observational study of adult patients with primary HPT receiving cinacalcet in clinical practice in a number of countries in Europe. Patients will be enrolled within 1 month of initiating cinacalcet treatment, and data will be collected prospectively for up to 1 year from initiation. Data will continue to be collected from patients discontinuing cinacalcet before the end of this period.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Amgen
• Treatments: Cinacalcet; Cinacalcet Hydrochloride

Criteria

Inclusion Criteria:

• at least 18 years of age at the time of first administration of cinacalcet

• patients with primary HPT who have initiated cinacalcet within 1 month before enrolment in the study

• provision of informed consent (if required)

Exclusion Criteria:

• previous use of cinacalcet (other than within 1 month before enrolment)

• diagnosed secondary HPT

• other known aetiology of hypercalcaemia (eg, sarcoidosis, tuberculosis)